Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer
Pfizer Inc. (NYSE: PFE) announced on July 22, 2026 that the U.S. Food and Drug...
Drug
Ribo Life Science Reports Positive Phase 2a Results for Vortosiran in Chronic Coronary Artery Disease
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced positive results from a Phase 2a...
Haisco Pharma Secures NMPA Approval for HSK39297 – First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that China’s National Medical Products Administration (NMPA)...
Takeda Secures World’s First NMPA Approval for Orexatone – Novel Oral OX2R Agonist for Type 1 Narcolepsy
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...
Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications
Youcare Pharmaceutical (SHA: 688658) announced that its investigational compound YKYY033 has received clinical trial approval...
Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC
Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the National Medical Products Administration (NMPA) has...
Gilead and Merck to Present Phase 3 ISLEND Trial Data for Once-Weekly Oral HIV Regimen at AIDS 2026 Conference
Gilead Sciences, Inc. (NASDAQ: GILD) and Merck & Co., Inc. (MSD; NYSE: MRK) announced that...
Alebund Pharmaceuticals Initiates Global Phase IIb Trial of AP306, First-in-Class Oral Pan-Phosphate Transporter Inhibitor for Hyperphosphatemia
Alebund Pharmaceuticals (HKG: 9637) announced that the first patient has been randomized and dosed in...
GSK Submits Bexsero Label Update to EMA for Single-Dose Booster in Adolescents and Adults Previously Vaccinated in Childhood
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced that the European Medicines Agency (EMA) has accepted a...
Beijing Wantai’s RSV Vaccine Receives NMPA Clinical Trial Acceptance for Lower Respiratory Tract Disease Prevention
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its clinical trial application...
Jacobio Pharmaceuticals’ JAB-8263 BET Inhibitor Proposed for NMPA’s Rare Disease “Caring Program” for Myelofibrosis Treatment
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) announced that...
Eisai and Biogen Secure FDA Approval for LEQEMBI Subcutaneous Autoinjector for Early Alzheimer’s Disease Initiation
Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) jointly announced that the U.S....
CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years
CanSino Biologics Inc. (HKG: 6185) announced that the National Medical Products Administration (NMPA) has accepted...
Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia
Easton Pharmaceutical Co., Ltd (SHA: 688513) announced that its generic version of remimazolam besylate has...
Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that its Investigational New Drug (IND) application...
Bio-Sincerity Secures NMPA Approval for Levetiracetam Extended-Release Granules – Pediatric-Friendly Epilepsy Treatment for Patients with Swallowing Difficulties
Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that its Category 2.2 modified drug Levetiracetam...
Allergan Aesthetics Secures European Commission Approval for Boey (trenibotulinumtoxinE) – First Rapid-Onset, Short-Duration Botulinum Neurotoxin Serotype E for Glabellar Lines
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that the European Commission has approved Boey...
GSK Reports Mixed Phase III Results for Camlipixant in Refractory Chronic Cough: CALM-1 Trial Meets Primary Endpoint While CALM-2 Falls Short
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced mixed results from the CALM-1 and CALM-2 Phase III...
Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis
Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that WP107 (Huperzine A Oral Solution)...
Jacobio Launches Phase Ib/III Trial of Pan-KRAS Inhibitor JAB-23E73 for KRAS-Mutated Pancreatic Cancer in Partnership with AstraZeneca
Jacobio Pharmaceuticals Group Co., Ltd. (HKG: 1167) announced that the first patient has been dosed...